Table 2.
Treatment‐emergent adverse events (TEAEs) reported by ≥ 5% of patients in either treatment group during the treatment period
| Primary system organ class | TEAEs | |
|---|---|---|
| Preferred term, n (%) | Placebo (N = 83) | Dupilumab (N = 82) |
| Any | 67 (81) | 63 (77) |
| Infections and infestations | 21 (25) | 28 (34) |
| Upper respiratory tract infection | 6 (7) | 9 (11) |
| Conjunctivitis | 4 (5) | 8 (10) |
| Eye disorders | 4 (5) | 9 (11) |
| Conjunctivitis allergic | 1 (1) | 7 (9) |
| Skin and subcutaneous tissue disorders | 40 (48) | 26 (31) |
| Atopic dermatitis | 38 (46) | 20 (24) |
| General disorders and administration site conditions | 5 (6) | 9 (11) |
| Injection site reaction a | 2 (2) | 7 (9) |
| Investigations | 16 (19) | 17 (21) |
| Proteinuria | 7 (8) | 7 (9) |
| Blood uric acid levels increased | 5 (6) | 1 (1) |
a
Includes injection site mass, injection site pain, or injection site swelling.